|
1
|
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
|
Blood
|
2002
|
2.38
|
|
2
|
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
|
Blood
|
2005
|
1.81
|
|
3
|
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
|
Cancer Res
|
2003
|
1.51
|
|
4
|
Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer.
|
Curr Drug Targets Cardiovasc Haematol Disord
|
2005
|
1.30
|
|
5
|
Targeting aurora kinases as therapy in multiple myeloma.
|
Blood
|
2007
|
1.19
|
|
6
|
The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
|
Br J Haematol
|
2007
|
1.01
|
|
7
|
Biological convergence of cancer signatures.
|
PLoS One
|
2009
|
0.97
|
|
8
|
Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility.
|
BMC Genomics
|
2008
|
0.97
|
|
9
|
The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs.
|
Endocr Relat Cancer
|
2006
|
0.90
|
|
10
|
Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.
|
Oncotarget
|
2013
|
0.87
|
|
11
|
Multifunctional proteins bridge mitosis with motility and cancer with inflammation and arthritis.
|
ScientificWorldJournal
|
2010
|
0.87
|
|
12
|
TACC3-TSC2 maintains nuclear envelope structure and controls cell division.
|
Cell Cycle
|
2010
|
0.85
|
|
13
|
Genetic interactions: the missing links for a better understanding of cancer susceptibility, progression and treatment.
|
Mol Cancer
|
2008
|
0.84
|
|
14
|
The cytoskeletal protein RHAMM and ERK1/2 activity maintain the pluripotency of murine embryonic stem cells.
|
PLoS One
|
2013
|
0.83
|
|
15
|
Intensity-based signal separation algorithm for accurate quantification of clustered centrosomes in tissue sections.
|
Microsc Res Tech
|
2006
|
0.82
|
|
16
|
Tubers from patients with tuberous sclerosis complex are characterized by changes in microtubule biology through ROCK2 signalling.
|
J Pathol
|
2014
|
0.76
|